Home/Filings/4/0001437749-25-022861
4//SEC Filing

Robinson Chandler 4

Accession 0001437749-25-022861

CIK 0001645469other

Filed

Jul 15, 8:00 PM ET

Accepted

Jul 16, 9:02 PM ET

Size

9.6 KB

Accession

0001437749-25-022861

Insider Transaction Report

Form 4
Period: 2025-07-14
Robinson Chandler
DirectorChief Executive Officer
Transactions
  • Exercise of In-Money

    Common Stock

    2025-07-14$0.01/sh+16,800$8490,272 total
  • Sale

    Common Stock

    2025-07-14$40.00/sh16,800$672,02073,472 total
  • Exercise of In-Money

    Stock Options

    2025-07-1416,8000 total
    Exercise: $0.01Exp: 2027-02-20Common Stock (16,800 underlying)
Holdings
  • Common Stock

    (indirect: See Footnote)
    822,255
Footnotes (4)
  • [F1]This transaction involved a cash exercise of stock options.
  • [F2]The shares were sold in multiple transactions at prices ranging from $40.00 to $40.25, inclusive. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
  • [F3]As a manager of Tactic Pharma LLC, Dr. Robinson may be deemed to share voting and dispositive power over these 822,255 shares. Dr. Robinson disclaims beneficial ownership of the 822,255 shares held by Tactic Pharma LLC, except to the extent of his pecuniary interest therein.
  • [F4]Reflects options to purchase up to 16,800 shares of common stock granted to Dr. Robinson on February 20, 2017, for his services as a director and officer of Monopar Therapeutics. The options vested 6/48ths upon the 6-month anniversary of the grant date and 1/48th per month thereafter.

Issuer

Monopar Therapeutics

CIK 0001645469

Entity typeother

Related Parties

1
  • filerCIK 0001727334

Filing Metadata

Form type
4
Filed
Jul 15, 8:00 PM ET
Accepted
Jul 16, 9:02 PM ET
Size
9.6 KB